Last reviewed · How we verify

Diphtheria-Tetanus Toxoids Adsorbed

Grifols Therapeutics LLC · FDA-approved active Biologic Quality 5/100

Diphtheria-Tetanus Toxoids Adsorbed, marketed by Grifols Therapeutics LLC, is a well-established vaccine in the preventive immunization market. A key strength is the protection it offers against diphtheria and tetanus, leveraging a proven mechanism of action. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.

At a glance

Generic nameDiphtheria-Tetanus Toxoids Adsorbed
SponsorGrifols Therapeutics LLC
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: